

木々津近久、別チャンに参戦!!!! 【恋愛セッションらぶさん】

●うら若き乙女に車掌な手が……!!



華やかに、艶やかに。凛として美しく。

この少女は――

!?



スペシャル読みきり

38P!

LOVE SESSION  
恋愛セッション  
ふふも

木々津克久



少年チャンピオン・コミックス

「ヘレンesp」全2巻

「名探偵マーニー」全10巻

「兄妹少女探偵と幽霊屋敷の怪奇事件簿」全7巻

大好評発売中!!



私ってそれなりの  
カッパしてあるて

男子とも普通に  
話せるし

スキンシップ  
多いし

多分  
モチでまん  
だと思っ



自分でいうのも  
なんだけど

男でくれば  
いい方だと思っ



胸はGカップ  
あるしね



けいけい  
腰りが痛んで  
くるんだよね

遊んでた  
ないんだよね























兄妹

100

李 强



**Table 1**

**Demographic characteristics of study population**

**N = 60**

**Age (years)**

Mean ± SD

78.9 ± 10.2

**Gender**

Male (%)

40

Female (%)

60

**Ethnicity**

Caucasian (%)

50

African American (%)

30

Hispanic (%)

10

Other (%)

10

**Education level**

High school or less (%)

30

Bachelor's degree (%)

40

Master's degree (%)

10

PhD (%)

10

**Marital status**

Married (%)

40

Single (%)

10

Widowed (%)

30

Divorced (%)

10

**Income**

< \$10,000 (%)

10

\$10,000–\$20,000 (%)

20

\$20,000–\$30,000 (%)

30

> \$30,000 (%)

40

**Health insurance**

Medicare (%)

90

Private (%)

10

**Comorbidities**

Hypertension (%)

40

Diabetes (%)

20

Cholesterol (%)

30

Heart disease (%)

10

Stroke (%)

10

Arthritis (%)

30

Pain (%)

20

Dementia (%)

10

Depression (%)

10

Anxiety (%)

10

Alcoholism (%)

10

Tobacco use (%)

10

Current smoker (%)

10

Former smoker (%)

90

Never smoker (%)

10

Smoker status unknown (%)

10

**Medication**

Antidepressant (%)

10

Antipsychotic (%)

10

Mood stabilizer (%)

10

Sedative (%)

10

Stimulant (%)

10

Insulin (%)

10

Beta-blocker (%)

10

Calcium channel blocker (%)

10

ACE inhibitor (%)

10

Statins (%)

10

Diuretics (%)

10

Anticoagulants (%)

10

Antibiotics (%)

10

Chemotherapy (%)

10

Radiation therapy (%)

10

Immunosuppressants (%)

10

Enzyme replacement therapy (%)

10

Gene therapy (%)

10

Cellular therapy (%)

10

Organ transplantation (%)

10

Other (%)

10

**Study site**

Urban (%)

40

Suburban (%)

30

Rural (%)

30

Other (%)

10

**Study duration**

Less than 1 year (%)

10

1–2 years (%)

20

2–3 years (%)

30

More than 3 years (%)

40

**Study phase**

Phase I (%)

10

Phase II (%)

20

Phase III (%)

30

Phase IV (%)

40

**Study sponsor**

FDA (%)

10

NIH (%)

20

Industry (%)

30

Academia (%)

40

Other (%)

10

**Study funding**

Government (%)

40

Industry (%)

30

Academia (%)

10

Non-profit (%)

10

Other (%)

10

**Study results**

Successful (%)

40

Unsuccessful (%)

60

**Study impact**

Highly influential (%)

10

Influential (%)

20

Not influential (%)

30

Unknown (%)

40

**Study conclusion**

Positive (%)

40

Negative (%)

60

**Study recommendation**

Repeat study (%)

10

Modify study (%)

20

Discontinue study (%)

30

Continue study (%)

40

**Study publication**

Published (%)

40

Not published (%)

60

**Study citation**

Cited (%)

40

Not cited (%)

60

**Study reference**

Referenced (%)

40

Not referenced (%)

60

**Study analysis**

Analysed (%)

40

Not analysed (%)

60

**Study interpretation**

Interpreted (%)

40

Not interpreted (%)

60

**Study discussion**

Discussed (%)

40

Not discussed (%)

60

**Study conclusion**

Concluded (%)

40

Not concluded (%)

60

**Study recommendation**

Recommended (%)

40

Not recommended (%)

60

**Study publication**

Published (%)

40

Not published (%)

60

**Study citation**

Cited (%)

40

Not cited (%)

60

**Study reference**

Referenced (%)

40

Not referenced (%)

60

**Study analysis**

Analysed (%)

40

Not analysed (%)

60

**Study interpretation**

Interpreted (%)

40

Not interpreted (%)

60

**Study discussion**

Discussed (%)

40

Not discussed (%)

60

**Study conclusion**

Concluded (%)

40

Not concluded (%)

60

**Study recommendation**

Recommended (%)

40

Not recommended (%)

60

**Study publication**

Published (%)

40

Not published (%)

60

**Study citation**

Cited (%)

40

Not cited (%)

60

**Study reference**

Referenced (%)

40

Not referenced (%)

60

**Study analysis**

Analysed (%)

40

Not analysed (%)

60

**Study interpretation**

Interpreted (%)

40

Not interpreted (%)

60

**Study discussion**

Discussed (%)

40

Not discussed (%)

60

**Study conclusion**

Concluded (%)

40

Not concluded (%)

60

**Study recommendation**

Recommended (%)

40

Not recommended (%)

60

**Study publication**

Published (%)

40

Not published (%)

60

**Study citation**

Cited (%)

40

Not cited (%)

60

**Study reference**

Referenced (%)

40

Not referenced (%)

60

**Study analysis**

Analysed (%)

40

Not analysed (%)

60

**Study interpretation**

Interpreted (%)

40

Not interpreted (%)

60

**Study discussion**

Discussed (%)

40

Not discussed (%)

60

**Study conclusion**

Concluded (%)

40

Not concluded (%)

60

**Study recommendation**

Recommended (%)

40

Not recommended (%)

60

**Study publication**

Published (%)

40

Not published (%)

60

**Study citation**

Cited (%)

40

Not cited (%)

60

**Study reference**

Referenced (%)

40

Not referenced (%)

60

**Study analysis**

Analysed (%)

40

Not analysed (%)

60

**Study interpretation**

Interpreted (%)

40

Not interpreted (%)

60

**Study discussion**

Discussed (%)

40

Not discussed (%)

60

**Study conclusion**

Concluded (%)

40

Not concluded (%)

60

**Study recommendation**

Recommended (%)

40

Not recommended (%)

60

**Study publication**

Published (%)

40

Not published (%)

60

**Study citation**

Cited (%)

40

Not cited (%)

60

**Study reference**

Referenced (%)

40

Not referenced (%)

60

**Study analysis**

Analysed (%)

40

Not analysed (%)

60

**Study interpretation**

Interpreted (%)

40

Not interpreted (%)

60

**Study discussion**

Discussed (%)

40

Not discussed (%)

60

**Study conclusion**

Concluded (%)

40

Not concluded (%)

60

**Study recommendation**

Recommended (%)

40

Not recommended (%)

60

**Study publication**

Published (%)

40

Not published (%)

60

**Study citation**

Cited (%)

40

Not cited (%)

60

**Study reference**

Referenced (%)

40

Not referenced (%)

60

**Study analysis**

Analysed (%)

40

Not analysed (%)

60

**Study interpretation**

Interpreted (%)

40

Not interpreted (%)

60

**Study discussion**

Discussed (%)

40

Not discussed (%)

60

**Study conclusion**

Concluded (%)

40

Not concluded (%)

60

**Study recommendation**

Recommended (%)

40

Not recommended (%)

60

**Study publication**

Published (%)

40

Not published (%)

60

**Study citation**

Cited (%)

40

Not cited (%)

60

**Study reference**

Referenced (%)

40

Not referenced (%)

60

大亮好評

鬼才タラシ 新選組  
第1巻!! 鬼面カラ〜!!



美しい犬

**Abstract**





# 名探偵マーニー



木々津寛久




11

ぼくらの探偵の会、面白くて探偵マーニーの活躍がすごいです

大好評  
発売中









SHOGAKUKAN  
SHOGAKUKAN  
SHOGAKUKAN

くまのesp

木々津寛久



2

新の平家物語のあらはれ

大好评  
発売中



オマサン  
この手  
なんだよ

放しな



おれにお茶でも

いいのか

なんつって

いや

悪いにしても  
デスティニーを  
感じる



うわ

急に  
開けんよ

姉ちゃんママが  
クレープフキーン  
帰ったって



どうか聞いて  
みまうかな

いきなりヤート  
ってのもハズかしい  
しなあ



レインなんか  
しもやって

うわ  
私リア充



.....



あと着てる制服から学校  
わかったので  
関係者のSNSから写真  
漁ってみます  
もしかしたら寝てるのが  
あるかも

明日学校いっしょに  
行こう  
その時 例の男子を  
誘えて

わかりました  
アキラの機嫌に  
乗ります

















毎月12日発売!!









1

19

「実は私は」シリーズ第19巻  
スリリングな恋愛セッション

大好評  
発売中











黄...









口元はつらいよ、でも顔をゆくんだ、次の瞬間いを見逃さないために、



平気だよ